Randomized Phase II Trials: What Does Randomization Gain?
- 20 March 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (9) , 1794-1795
- https://doi.org/10.1200/jco.2005.10.956
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2005
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Early selection in a randomized phase II clinical trialStatistics in Medicine, 2002
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989